Related Experiment Video
Updated: Jul 15, 2025
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.2K
Stem cell therapy in pulmonary hypertension: current practice and future opportunities
Ruixuan Zheng1,2,3,4, Tingting Xu1,2,3,4, Xinghong Wang1,2,3
1Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, China.
Summary
Novel stem cell therapies show promise for treating pulmonary hypertension (PH), a serious condition with high mortality. This review explores preclinical successes and ongoing clinical trials, addressing challenges for future widespread use.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Pulmonary Medicine
Background:
- Pulmonary hypertension (PH) is a progressive disease leading to right-sided heart failure.
- Current drug therapies offer limited improvement in survival rates for PH patients.
- There is a critical need for innovative treatments to improve long-term outcomes in PH.
Purpose of the Study:
- To review the latest preclinical advancements in stem cell therapies for PH.
- To analyze the therapeutic effects observed in ongoing clinical trials for PH stem cell treatments.
- To discuss challenges and future directions for the large-scale application of stem cell therapies in PH.
Main Methods:
- Literature review of preclinical studies on stem cell therapies for PH.
- Analysis of data from ongoing clinical trials involving stem cells for PH.
- Discussion of challenges related to the clinical translation and scalability of these therapies.
Main Results:
- Stem cell therapies, including mesenchymal stem cells, endothelial progenitor cells, and induced pluripotent stem cells, demonstrate therapeutic potential in preclinical PH models.
- Clinical trials are underway, investigating the efficacy and safety of various stem cell approaches for PH.
- Early findings suggest potential benefits in improving haemodynamic parameters and possibly survival, though large-scale data is pending.
Conclusions:
- Stem cell therapy represents a promising avenue for novel PH treatment strategies.
- Further research and clinical trials are essential to overcome challenges and enable widespread application.
- Optimizing stem cell types, delivery methods, and understanding long-term effects are crucial for future success in managing PH.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
249
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
249
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:30Pulmonary Hypertension: Classification and Pathogenesis
207
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
207
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203